EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2

Yang Li, Chitra Saran, Xiaoyan Chu, Rosa I Sanchez, Alana F Thomas, Russ P Carstens, Mary L Pisculli, Stephanie O Klopfer, Zhi Jin Xu, Rima Lahoulou, Rebeca M Plank

Drug Metabolism and Disposition · 2026-06 · 54 (6) · 100303

DOI: 10.1016/j.dmd.2026.100303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-06. Verfasst von Yang Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co, Inc, Rahway, New Jersey. Hauptthemen laut MEDLINE: Organic Cation Transporter 2, Triazoles, Glomerular Filtration Rate, Pyridones. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doravirine (DOR), a potent nonnucleoside reverse transcriptase inhibitor for HIV-1 treatment, is primarily metabolized by cytochrome P450 3A enzymes to form doravirine carboxylic acid metabolite (M9), the major plasma metabolite excreted in urine. To investigate the estimated glomerular filtration rate decrease observed in phase 3 DOR studies, we investigated DOR and M9 interactions with renal transporters organic cation transporter 2 (OCT2), organic anion transporter 2 (OAT2), and multidrug and toxin extrusion proteins 1 and 2K (MATE1 and MATE2K). In vitro assays were conducted in OCT2- and OAT2-transfected human embryonic kidney 293 (HEK293) cells and MATE1- and MATE2K-transfected Madin-Darby canine kidney II cells. The inhibitory potency (half-maximal inhibitory concentration [IC50]) of DOR and M9 on OCT2-, OAT2-, MATE1-, and MATE2K-mediated uptake of creatinine or metformin were measured, whereas substrate-dependent inhibition was assessed for OCT2 and MATE1. DOR inhibited OCT2-mediated creatinine uptake with an IC50 of 6.9 ± 0.8 μM, approximately 6.2-fold lower than that observed using metformin as probe. DOR also inhibited OAT2 at concentrations higher than clinically relevant (IC50 of 28.7 ± 4.9 μM). DOR did not inhibit MATE1-mediated creatinine uptake (IC50 >100 μM). M9, at concentrations higher than clinically relevant, inhibited OAT2-mediated creatinine uptake (IC50 of 18.0 ± 2.1) but did not inhibit creatinine or metformin uptake by OCT2, MATE1, or MATE2K (IC50 >30 μM for all). In conclusion, at clinically relevant exposures, DOR exhibited substrate-dependent inhibition of creatinine transport via OCT2, which could explain the slight decrease in calculated estimated glomerular filtration rate observed with DOR treatments, without reduction in renal function. SIGNIFICANCE STATEMENT: At clinically relevant concentrations, doravirine inhibits the renal transporter organic cation transporter 2 in a substrate-dependent manner, but not organic anion transporter 2, multidrug and toxin extrusion proteins 1 and 2K, indicating that doravirine-associated estimated glomerular filtration rate reductions are caused by inhibition of renal creatinine transport and do not reflect a reduction in renal function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Organic Cation Transporter 2TriazolesGlomerular Filtration RatePyridonesReverse Transcriptase InhibitorsHumansDogsHEK293 CellsAnimalsMadin Darby Canine Kidney CellsOrganic Cation Transport ProteinsKidneyCreatinineMetformin

Stichwörter der Autor:innen

AntiretroviralDoravirineEstimated glomerular filtration rateHuman immunodeficiency virus-1Organic cation transporter 2Renal transporters

Substanzen

Organic Cation Transporter 2TriazolesdoravirineOrganic Cation Transport ProteinsPyridonesSLC22A2 protein, humanSLC47A1 protein, humanReverse Transcriptase InhibitorsSLC47A2 protein, humanCreatinine

Autor:innen und Institutionen

  • Merck & Co, Inc, Rahway, New Jersey.
  • Merck & Co, Inc, Rahway, New Jersey. Electronic address: rebeca.plank@merck.com.

Förderung

  • Merck

Zitieren

APA

Li, Y., Saran, C., Chu, X., Sanchez, R. I., Thomas, A. F., Carstens, R. P., Pisculli, M. L., Klopfer, S. O., Xu, Z. J., Lahoulou, R., & Plank, R. M. (2026). Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2. Drug Metabolism and Disposition, 54(6), 100303. https://doi.org/10.1016/j.dmd.2026.100303

Vancouver

Li Y, Saran C, Chu X, Sanchez RI, Thomas AF, Carstens RP, et al. Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2. Drug Metabolism and Disposition. 2026;54(6):100303. doi:10.1016/j.dmd.2026.100303

BibTeX
@article{Li2026,
  author = {Li, Yang and Saran, Chitra and Chu, Xiaoyan and Sanchez, Rosa I and Thomas, Alana F and Carstens, Russ P and Pisculli, Mary L and Klopfer, Stephanie O and Xu, Zhi Jin and Lahoulou, Rima and Plank, Rebeca M},
  title = {Reduction in estimated glomerular filtration rate observed with doravirine is caused by inhibition of organic cation transporter 2},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {6},
  pages = {100303},
  doi = {10.1016/j.dmd.2026.100303}
}
Kostenlos starten →